Literature DB >> 10446086

Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension.

R A Ariëns1, H P Kohler, M W Mansfield, P J Grant.   

Abstract

Factor (F) XIII covalently cross-links and stabilizes the fibrin-clot. Recent evidence suggests a role for FXIII in atherothrombotic diseases, but no information is available regarding the association of FXIII with common risk factors. The aim of this study was to investigate the relationship of FXIII with age, sex, smoking, and hypertension. Plasma levels of FXIII A-subunit antigen, FXIII B-subunit antigen, and FXIII cross-linking activity were measured in 612 healthy individuals (250 men and 362 women). FXIII A- and B-subunit levels were correlated significantly with age in both men (r=0.21, P=0.001, and r=0.17, P=0.008, respectively) and women (r=0.20, P<0.0005, and r=0.13, P=0.011, respectively). FXIII B-subunit levels and activity were correlated significantly with FXIII A-subunit levels (r=0.60, P<0.0005, and r=0.14, P<0.0005, respectively) and fibrinogen (r=0.26, P<0.0005, and r=0.14, P=0.001, respectively). Women had higher levels of FXIII A-subunit (111.8% versus 105.2%, P<0.01) and B-subunit (109.5% versus 103.8%, P<0.01) than did men. FXIII A-subunit was significantly increased in smokers (117.0% versus 104.6%, P<0.0005) and in subjects with hypertension (114.9% versus 107.8%, P<0.05). In a multiple regression model, FXIII A-subunit was significantly increased by female sex (+6.4%, P<0.007), smoking (+12.3%, P<0.0005), and increasing age (+3.7% per 10 years, P<0.0005). FXIII B-subunit was significantly related to female sex and fibrinogen, and FXIII activity was significantly related to fibrinogen levels. In conclusion, the FXIII A-subunit level increases significantly with female sex, age, and smoking, whereas FXIII B-subunit and FXIII activity are associated with FXIII A-subunit level and fibrinogen. Although evidence for a causal relationship between FXIII A-subunit and vascular disease is not available, these results might suggest a role for elevated FXIII A-subunit levels in the pathogenesis of vascular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446086     DOI: 10.1161/01.atv.19.8.2012

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Hazelnut-enriched chocolate improves flow-mediated artery dilatation via inhibition of oxidative stress.

Authors:  Matteo Becatti; Claudia Fiorillo
Journal:  Intern Emerg Med       Date:  2018-09-08       Impact factor: 3.397

2.  Increased thrombosis susceptibility and altered fibrin formation in STAT5-deficient mice.

Authors:  Sarah M Nordstrom; Brian A Holliday; Brandon C Sos; James W Smyth; Robert E Levy; Jonathan W Dukes; Susan T Lord; Ethan J Weiss
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

3.  Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains.

Authors:  Mohammad Suhail Akhter; Sneha Singh; Hamideh Yadegari; Vytautas Ivaskevicius; Johannes Oldenburg; Arijit Biswas
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

Review 4.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

5.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

6.  The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.

Authors:  Anke-Hilse Maitland-van der Zee; Bas J M Peters; Amy I Lynch; Eric Boerwinkle; Donna K Arnett; Suzanne Cheng; Barry R Davis; Catherine Leiendecker-Foster; Charles E Ford; John H Eckfeldt
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

7.  Elimination of coagulation factor XIII from fibrinogen preparations.

Authors:  E L Smith; B Cardinali; L Ping; R A S Ariëns; H Philippou
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

8.  Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.

Authors:  Annabel Blasi; Vishal C Patel; Eva N H E Spanke; Jelle Adelmeijer; Marilena Stamouli; Ane Zamalloa; Eleanor Corcoran; Andrea Calvo; Javier Fernandez; William Bernal; Ton Lisman
Journal:  Liver Int       Date:  2021-12-20       Impact factor: 8.754

9.  Factor XIII polymorphism and risk of aneurysmal subarachnoid haemorrhage in a south Indian population.

Authors:  Arati Suvatha; M K Sibin; Dhananjaya I Bhat; K V L Narasingarao; Vikas Vazhayil; G K Chetan
Journal:  BMC Med Genet       Date:  2018-09-05       Impact factor: 2.103

10.  Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease.

Authors:  Ton Lisman; Bethlehem Arefaine; Jelle Adelmeijer; Ane Zamalloa; Eleanor Corcoran; John G Smith; William Bernal; Vishal C Patel
Journal:  J Thromb Haemost       Date:  2020-11-29       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.